614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

Abstract

were shorter in gBRCA2 carriers who also present somatic BRCA2-RB1 codel or MYC amplification compared with gBRCA2 without such alterations. SImilar results were observed in NC (Table ). MVA model confirmed the independent prognostic value of somatic BRCA2-RB1 codel (HR 4.13; p¼0.004) and MYC amplif (HR 2.27; p¼0.033) for CSS.Conclusions: PROREPAIR-A is the largest series of gBRCA2 tumors assembled to date to explore associations between somatic alterations and clinical outcomes in PC. Our results suggest that somatic BRCA2-RB1 codel and MYC amplification define an aggressive subtype of PC with poor clinical outcomes in both gBRCA2 and NC.

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD

“…Although olaparib has recently been approved in the US for this population, there is growing evidence that these patients may benefit from the use of taxanes at some point during their course of treatment [2,25]. In two large retrospective, international, observational studies, patients with mCRPC tested for germline DNA damage repair mutations had similar progression-free survival and response rate with docetaxel regardless of whether they did or did not have germline DNA damage repair mutations [26,27]. In this small, exploratory, real-world evidence analysis, the improved treatment duration of cabazitaxel compared with docetaxel in the second-or third-line treatment of patients with rare mutation subtypes may suggest greater activity of cabazitaxel in these patients with aggressive disease, though the data should still be considered hypothesis generating due to limited patient numbers and our inability to track progression risk.…”